An ultrasensitive NanoLuc-based luminescence system for monitoring  throughout its life cycle by unknown
De Niz et al. Malar J  (2016) 15:232 
DOI 10.1186/s12936-016-1291-9
METHODOLOGY
An ultrasensitive NanoLuc-based 
luminescence system for monitoring 
Plasmodium berghei throughout its life cycle
Mariana De Niz*, Rebecca R. Stanway, Rahel Wacker, Derya Keller and Volker T. Heussler
Abstract 
Background: Bioluminescence imaging is widely used for cell-based assays and animal imaging studies, both in 
biomedical research and drug development. Its main advantages include its high-throughput applicability, afford-
ability, high sensitivity, operational simplicity, and quantitative outputs. In malaria research, bioluminescence has been 
used for drug discovery in vivo and in vitro, exploring host-pathogen interactions, and studying multiple aspects of 
Plasmodium biology. While the number of fluorescent proteins available for imaging has undergone a great expan-
sion over the last two decades, enabling simultaneous visualization of multiple molecular and cellular events, expan-
sion of available luciferases has lagged behind. The most widely used bioluminescent probe in malaria research is 
the Photinus pyralis firefly luciferase, followed by the more recently introduced Click-beetle and Renilla luciferases. 
Ultra-sensitive imaging of Plasmodium at low parasite densities has not been previously achieved. With the purpose of 
overcoming these challenges, a Plasmodium berghei line expressing the novel ultra-bright luciferase enzyme NanoLuc, 
called PbNLuc has been generated, and is presented in this work.
Results: NanoLuc shows at least 150 times brighter signal than firefly luciferase in vitro, allowing single parasite 
detection in mosquito, liver, and sexual and asexual blood stages. As a proof-of-concept, the PbNLuc parasites were 
used to image parasite development in the mosquito, liver and blood stages of infection, and to specifically explore 
parasite liver stage egress, and pre-patency period in vivo.
Conclusions: PbNLuc is a suitable parasite line for sensitive imaging of the entire Plasmodium life cycle. Its sensitiv-
ity makes it a promising line to be used as a reference for drug candidate testing, as well as the characterization of 
mutant parasites to explore the function of parasite proteins, host-parasite interactions, and the better understanding 
of Plasmodium biology. Since the substrate requirements of NanoLuc are different from those of firefly luciferase, dual 
bioluminescence imaging for the simultaneous characterization of two lines, or two separate biological processes, is 
possible, as demonstrated in this work.
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Background
Malaria is a life-threatening disease caused by Plas-
modium parasites, which are transmitted to humans 
through the bite of infected Anopheles mosquitoes. The 
five Plasmodium species able to infect humans are Plas-
modium falciparum, Plasmodium vivax, Plasmodium 
malariae, Plasmodium ovale and Plasmodium knowlesi, 
all of which vary in their clinical manifestations and 
severity. Currently, there are 200 million clinical cases 
and over 500,000 deaths reported per year, most of which 
occur in sub-Saharan Africa [1]. Major challenges pres-
ently existing for malaria elimination programs include 
the emergence of parasites showing multidrug-resistance 
to current anti-malarials, increasing development of 
resistance by mosquitoes to insecticides, and the pres-
ence and widespread distribution of parasite species such 
as P. vivax, that produce dormant stages in the liver and 
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are thus capable of inducing multiple relapses [2]. The 
malaria eradication agenda envisages advances in vaccine 
development against pre-erythrocytic stages, anti-malar-
ial compound development, vector control, and sensitive 
diagnostic and surveillance tools in endemic areas [3]. 
In addition, there is a pressing need for improving the 
general understanding of parasite biology, and the iden-
tification of targets for generation of genetically attenu-
ated parasites (GAPs) and anti-malarial activity. Animal 
models of malaria, and particularly rodent models, have 
proven to be extremely valuable tools for basic research 
on parasite and host biology, host-pathogen interactions, 
and anti-malarial drug activity [4–6].
Bioluminescence is found in nature in a large diver-
sity of organisms. The generation of light occurs when a 
luminogenic substrate is oxidized, resulting in the emis-
sion of photons that can be accurately measured by 
sensitive specialized equipment such as luminometers 
or CCD cameras. Plasmodium falciparum and several 
rodent Plasmodium strains have already been engineered 
to express bioluminescent reporters. The uses of biolu-
minescence in Plasmodium were recently reviewed by 
Siciliano and Alano [7]. Among the applications of bio-
luminescence in Plasmodium research, some of the most 
relevant studies include the in vivo and in  vitro assess-
ment of parasite growth in liver [8–15] and blood stages 
[14]; schizont sequestration in  vivo ([16–19], De Niz 
et  al., unpublished); analysing stage-specificity of pro-
moters and other regulatory elements [20–33]; testing 
anti-malarial activity of drugs targeting liver [11, 34–40], 
and blood stage parasites [41–46]; screening for trans-
mission-reducing activity of anti-malarials [47–50]; func-
tional studies of parasite proteins and/or the adequacy 
of parasite attenuation by genetic manipulation ([16, 18, 
51, 52]; De Niz et  al., unpublished); evaluation of anti-
malarial immunity [53–55]; visualization of sporozoites 
in the skin [56], and specific differentiation of gametocyte 
stages (I-V) [47].
The most widely used luciferase in Plasmodium 
research has by far been firefly luciferase, isolated from 
the firefly Photinus pyralis [57, 58]. Other luciferases also 
previously used in malaria include Renilla luciferase, iso-
lated from the sea pansy Renilla reniformis [59, 60], and 
Click beetle luciferases isolated from the beetle Pyroph-
orus plagiophthalamus [61, 62]. A wide variety of living 
organisms, including arthropods, annelids, molluscs, fish, 
cnidarians, protists, as well as various microorganisms, 
are able to produce light or ‘bioluminesce’. Biolumines-
cent proteins from many of these organisms have been 
isolated for use in biomedical research. Figure  1 shows 
the various luciferases currently available, with their 
key luminescence properties (Diagram references [63–
69]). Despite the wide variety of organisms capable of 
producing luminescent proteins, bioluminescence imag-
ing in biomedical research is thought to be relatively lim-
ited for simultaneous measurements. This is in contrast 
to the wide variety of proteins available for fluorescence 
imaging. In addition to the luciferases listed in Fig.  1, 
novel artificial methods to shift the emission spectra of 
currently existing luciferases and the generation of arti-
ficial luciferases and substrates, will continue to expand 
the field of luminescence imaging and its application to 
various areas of research, including malaria.
While firefly luciferase has provided enormous advan-
tages for assay scalability in  vivo and in  vitro and has 
multiple applications in biomedical research, recently, a 
novel 19 kDa enzyme named NanoLuc, was synthetically 
generated following purification of the natural enzyme 
from the deep sea shrimp Oplophorus gracilorostris. 
NanoLuc possesses 150-fold brighter luminescent signal 
than firefly or Renilla [70]. Aside from its high level of 
luminescence, NanoLuc is able to sustain signal intensity 
with a relatively long half-life of 2  h, and generates low 
background signal making it an efficient, highly stable, 
and highly sensitive assay. In addition to optimal activ-
ity of the enzyme, suitable substrates were investigated to 
further maximize protein stability and light output. The 
coelenterazine analogue furimazine, in combination with 
NanoLuc, was found to produce the brightest output, 
and enhanced stability. Despite its relatively recent intro-
duction, NanoLuc has already been used to generate a 
wide variety of transgenic organisms and cells for in vivo 
[71–78] and in vitro [79–96] studies, most of which have 
reported the considerable advantages of NanoLuc as a 
luminescent system, including the possibility of doing 
dual or multiplex assays in combination with Gaussia 
[82], or firefly [72, 94] luciferases. Among the transgenic 
organisms using this technology, NanoLuc-expressing P. 
falciparum parasites (termed PfNLuc) have already been 
generated, and used for inhibitory compound screening 
assays, and protein secretion studies [97].
In this work, NanoLuc is introduced as a reporter in 
Plasmodium berghei. PbNLuc parasites were generated 
to constitutively express NanoLuc under the ef1α pro-
moter. All stages of the P. berghei life cycle were assessed 
in terms of minimum detection limit of the assay at low 
parasite densities, kinetics of parasite development, and 
sensitive detection of P. berghei egress in its transition 
from the liver to the blood stages. Also as proof of con-
cept, the assay is used in a dual format together with fire-
fly-luciferase to study co-infections in vivo.
Methods
Ethics statement
Balb/c and C57BL/6 studies were carried out under the 
approval of the Animal Research Ethics Committee of the 
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Canton Bern, Switzerland (Permit Number: 91/11 and 
81/11); the University of Bern Animal Care and Use Com-
mittee, Switzerland; and the German Tierschutzgesetz (Ani-
mal Rights Laws). For all studies, females 5–8 weeks of age, 
weighing 20–30 g at the time of infection were used. Mice 
were purchased from Harlan or Charles River laboratories. 
All measurements involving in vivo bioluminescence were 
performed under isofluorane anaesthesia. Blood feeding 
was performed under ketavet/dorbene anaesthesia, and all 
efforts were made to minimize suffering.
Fig. 1 Luminescent proteins used in biomedical research
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Plasmid construction
The pL0017 vector (obtained through the Malaria 
Research and Reference Reagent Resource Center [(MR4; 
http://www.mr4.org/) (MR4 no., MRA-786)] allows con-
stitutive expression of GFP in P. berghei parasites, under 
the control of the ef1α promoter, either by episomal 
expression, or by integration of the plasmid sequence into 
the cssu/dssu (c-type small subunit/d-type small subunit) 
ribosomal gene locus of the parasite. The NLuc sequence 
was amplified from the pNL1.1 (NLuc) vector (Promega) 
using Phusion ® Taq High-Fidelity DNA polymerase, 
and the primers 5′-GGATCCATGGTCTTCACACTC 
GAAGATTTC-3′ and 5′-TCTAGATTACGCCAGAAT 
GCGTTGCG-3′. The pL0017 plasmid was cut at BamHI 
and XbaI sites, and the GFP sequence excised. NLuc 
was introduced into the pJET vector as an intermediate 
step, and then introduced into the pL0017 vector using 
the BamHI and XbaI restriction sites to create plasmid 
pL0017-NLuc. Plasmid DNA was linearized with ApaI 
and SacII, and 5–10  μg of linearized plasmid DNA was 
used for transfection of either schizonts or detached cells.
Schizont transfection
Six to eight-week old Balb/c mice were infected with Pbm-
CherryHsp70 [98] until the parasitaemia reached 5–6  %. 
Mice were bled by intracardiac puncture and schizont cul-
tures generated. Schizonts were then isolated as previously 
published [99]. Parasites were transfected with pL0017-
NLuc, and the transfectant injected into one Balb/c mouse 
by intravenous injection. One day post-infection, the 
mouse was treated with 70 mg/ml pyrimethamine in drink-
ing water for positive selection of PbmCherryHsp70NLucef1α.
Detached cell transfection
An alternative method tested for the first time, was 
transfection of liver stage detached cells. HepG2 cells 
were seeded in a 24-well plate (Greiner BioOne) and 
the next day infected with PbmCherryHsp70 sporozo-
ites. Infected HepG2 cells were maintained as described 
in further sections. Sixty-five hours after infection and 
upon completion of the liver stage of infection, detached 
cells or merosomes were collected from the supernatant 
and centrifuged for 10  s at 1600  rpm. Merosomes and 
detached cells were then transfected as previously pub-
lished [99], with 5–10 µg of linearized pL0017-NLuc and 
injected into the tail vein of a naïve Balb/c mouse. One 
day post-infection, the mouse was treated with 70 mg/ml 
pyrimethamine in drinking water for positive selection of 
PbmCherryHsp70NLucef1α.
Clone selection
For clone selection, Anopheles stephensi mosquito 
feeds were performed as described below, and at day 
18 post-feed, mosquito salivary glands were dissected 
for infection of HepG2 cells (as described below). Upon 
completion of the liver stages, six individual detached 
cells were isolated using previously published meth-
odology [100], and injected into separate mice. 10,000 
infected red blood cells (iRBCs) were isolated from each 
mouse, and probed using the NanoGlo™ (Promega) assay 
as described below. The clones consistently displaying the 
brightest signal were selected for downstream analyses.
Luciferase assay
Transgenic parasites from all stages were lysed in 20 μl of 
1 ×  Passive Lysis Buffer (1 ×  PLB) (Promega) as recom-
mended by the manufacturer. For firefly luciferase meas-
urements, these 20  μl lysates were mixed with 100  μl of 
Luciferase assay reagent, containing the luciferase assay 
substrate luciferin dissolved in Luciferase Assay Buffer 
(LAB), and measured within 30  s in an IVIS Lumina II 
equipment, with 45 s exposure time, and gain adjusted to 
maximum. For NanoLuc assays, lysates were mixed with 
50 μl of the NanoGlo™ luciferase assay reagent. The Nano-
Glo™ luciferase assay reagent was optimized for maximum 
signal by adding one volume of NanoGlo™ luciferase assay 
substrate to 50 volumes of NanoGlo™ Luciferase assay 
buffer, as recommended by the manufacturer. Optimization 
for imaging parasites at low concentrations included both, 
finding the minimum concentration of parasites detect-
able in the 1:50 assay mixture, and the maximum dilution 
of NanoGlo™ luciferase assay substrate that would still ena-
ble optimal signal detection while allowing for significant 
cost reductions and maximum use. Concentrations tested 
other than 1:50, included 1:100, 1:200, 1:500 and 1:1000, 
all of which allowed detection of parasites at low, medium 
and high concentrations. Single parasites of all Plasmodium 
stages were only detected using maximum detection set-
tings (45 s exposure, and 1:50 NanoLuc concentration).
Parasite maintenance in mosquitoes
Balb/c mice were treated with phenylhydrazine three 
days prior to i.p infection with P. berghei express-
ing mCherry and either Firefly or NanoLuc luciferases 
(PbmCherryHsp70FLucef1α or PbmCherryHsp70NLucef1α). 
After 3  days of infection, exflagellation was assessed. 
The infected mice were then each used to feed 100–150 
Anopheles stephensi female mosquitoes. Mice were 
anaesthetized with a combination of Ketasol/Dorbene 
anaesthesia, and euthanized with CO2 after completion 
of the feed. Afterwards, mosquitoes were fed until use 
with 8 % fructose containing 0.2 % PABA.
In vitro luciferase assays for oocyst measurements
Seven to nine days following the blood meal on infected 
mice, 100 mosquitoes from three different cages infected 
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either with PbmCherryHsp70NLucef1α (PbNLuc) or 
PbmCherryHsp70FLucef1α (PbFLuc) were sorted using 
an epifluorescence binocular microscope (Olympus 
SZX10 using a U-HGLGPS UV lamp), and mCherry-
positive mosquitoes selected, dissected and the mid-
guts isolated to evaluate oocyst numbers and luciferase 
expression. For correlation between fluorescence and 
luminescence assays, 100 dissected midguts were trans-
ferred in 1 × PBS onto a coverslip, and imaged immedi-
ately using a 20× objective, of an upright epifluorescence 
microscope (Leica DM 5500 B). Four z-stacks from 
each midgut were obtained to allow for quantification 
of oocytsts over the entire midgut area. Upon finalizing 
image acquisition, midguts were immediately transferred 
to the 20  μl of 1  ×  PLB for downstream analysis. For 
prevalence assays, 200 mosquitoes were not sorted prior 
to dissection or homogenization, but randomly selected 
from 3 independent feed cages harbouring no more than 
150 mosquitoes each. Bioluminescent measurements 
of all samples were performed in 96-well, flat-bottom, 
non-binding, black plates (Greiner BioOne). For consist-
ent and unsaturated oocyst measurements, the optimal 
NanoGlo™ luciferase assay substrate dilution used for 
probing the midguts was 1:1000. The midguts of unin-
fected mosquitoes were used as negative controls.
In vitro luciferase assays for sporozoite measurements 
and limit of detection
Sixteen to 28  days post-feed, mosquitoes infected 
with PbmCherryHsp70NLucef1α (PbNLuc) or 
PbmCherryHsp70FLucef1α (PbFLuc) were dissected for 
extraction of their salivary glands. Sporozoites were 
counted using a Neubauer chamber, and serial dilutions 
of sporozoites made in 1 ×  PBS. The final diluted sam-
ples were centrifuged and the pellet (10  μl) transferred 
to 20 μl of 1 × PLB for downstream analysis. For imag-
ing, a range between 1 and 100,000 sporozoites, different 
dilution sets from 20 separate mosquitoes were divided 
into independent 96-well plates to enable different imag-
ing settings for maximum signal detection of samples 
at low densities (i.e. 1–100 sporozoites), while avoiding 
pixel saturation of samples at high densities (i.e., 10,000–
100,000 sporozoites). For consistent and unsaturated 
sporozoite measurements, the optimal NanoGlo™ lucif-
erase assay substrate dilution used was 1:250. Salivary 
glands of uninfected mosquitoes were used as negative 
controls.
In vitro luciferase assays for liver stage measurements
Human hepatoma cells (HepG2 line) (European Col-
lection of Cell Culture) were maintained in complete 
Minimum Essential Medium (cMEM) containing Earle’s 
Salts, supplemented with 10  % heat-inactivated fetal 
calf serum (FCS), 2  mM  l-Glutamine, and 100  U Peni-
cillin, 100  μg/ml Streptomycin (all from PAA laborato-
ries, E15-024, A15-101, P11-010, M11-004). Cells were 
kept at 37 °C in a 5 % CO2 cell incubator and were split 
every 4  days by treatment with accutase. For in  vitro 
bioluminescence assays, 30,000 cells were seeded into 
wells of 24-well plates, and infected 18-24  h afterwards 
with 10,000 PbmCherryHsp70NLucef1α (PbNLuc) or 
PbmCherryHsp70FLucef1α (PbFLuc) sporozoites. Upon 
infection, sporozoites and HepG2 cells were incubated 
together in cMEM  +  2.5  μg/ml amphothericin (AT-
MEM) to avoid fungal contamination. At 6, 12, 24, 36, 
48, and 56 h post-infection, total parasite numbers were 
quantified by fluorescence, and HepG2 cells detached 
using 100  μl of accutase. Cells were quantified using a 
Neubauer chamber, and specific parasite numbers iso-
lated (ranging from 1 to 1000). The diluted samples con-
taining the desired number of parasites were lysed in 
20 μl of 1 × PLB for downstream analysis. For isolation 
of single later stage parasites (36  h onwards), the cells 
detached by accutase treatment were imaged using an 
epifluorescence microscope to ensure capture of a sin-
gle parasite (in a method analogous to that described by 
Stanway et al. [100]. Lysates were transferred to 96-well 
black plates, and imaged immediately at every time point 
using an IVIS Lumina II. For consistent and unsaturated 
measurements, the optimal NanoGlo™ luciferase assay 
substrate dilution used for probing liver stage parasites 
was 1:250. Uninfected HepG2 cells were used as negative 
controls.
In vitro luciferase assays for liver stage egress, detached 
cell formation and merozoite numbers
In order to investigate detached cell formation by 
PbmCherryHsp70NLucef1α (PbNLuc) parasites, HepG2 
cells were infected as previously described, and at 
63–65  h post-infection, the supernatant of the 24 well-
plates, where detached cells (representing successfully 
completed liver stage development) are located, was 
collected for downstream analysis. For collection of sin-
gle detached cells, the method previously published by 
Stanway et  al. [100] was used. Prior to collection and 
lysis, individual detached cells were imaged by fluores-
cence using an inverted fluorescence microscope (Leica 
DMI 6000B with an incubation chamber), and a series 
of 3–4 z-stacks obtained for measurements. Upon col-
lection, individual detached cells were lysed in 1xPLB, 
and assayed by luminescence. For consistent and unsatu-
rated measurements, the optimal NanoGlo™ luciferase 
assay substrate dilution used for probing detached cells 
was determined to be 1:250. In order to determine the 
number of merozoites per individual detached cell, a 
previously published method [101] was used. Namely, 
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from the fluorescence images, the radius of the detached 
cell was determined, and the volume of the detached 
cell (VDC) was calculated by the formula VDC = 43pir3 . 
Sturm et  al. previously determined the volume of indi-
vidual merozoites (Vm) to be equal to 2.66  μm3 [101]. 
An approximation of the number of merozoites (Nm) per 
detached cell is, therefore, calculated as Nm = VDCVm .
In vivo luciferase assays for liver stage egress 
and pre‑patency determination
To determine the pre-patency period detectable by 
NanoLuc, a total of 20 mice were infected with 5000 
sporozoites from PbmCherryHsp70NLucef1α-infected mos-
quitoes by tail-vein injection. 2  µl of blood were taken 
by tail puncture at 12 and 24 h post-infection and from 
36  h onwards, 4-hourly measurements were made until 
70  h post-infection. This blood was lysed in 20  µl of 
1 × PLB, and for maximum sensitivity, probed with 1:50 
NanoGlo™ luciferase assay substrate dilutions. To deter-
mine in  vitro sensitivity, individual detached cells from 
infected HepG2 cultures (described above) were isolated 
as previously described [100], and imaged using an epi-
fluorescence microscope for downstream volume cal-
culations. Following imaging, each individual detached 
cell was transferred to 20 µl of 1 × PLB. Images of blood 
and detached cells were acquired immediately using an 
IVIS Lumina II equipment. For maximum sensitivity for 
appearance of parasites in the blood, a 1:50 dilution of 
NanoGlo™ luciferase assay substrate was used.
In vitro luciferase assays for blood stage measurements
For blood stage measurement curves and assays for 
detecting the minimum sensitivity limit, parasites 
were diluted to ranges between 1 and 100,000. Each 
of the diluted samples were lysed in 1  ×  PLB, and 
imaged immediately. For calculation of the parasitae-
mia, three separate groups of five mice each (Balb/c 
and C57BL/6) were infected with 106 schizonts of either 
PbmCherryHsp70NLucef1α, or PbmCherryHsp70FLucef1α. 
2 µl of blood were obtained daily by tail vein prick, lysed 
in 20 µl of 1 × PLB, and probed immediately. Every day, 
thin smears were made on glass coverslips, and Giemsa 
stains performed for microscopic quantification of para-
sitaemia to assess correlations between luminescence 
values and parasitaemia in blood smears. For analy-
sis of sequestration, mice were injected with either 106 
PbmCherryHsp70NLucef1α schizonts, or with a mixture of 
PbmCherryHsp70NLucef1α and PbmCherryHsp70FLucef1α 
(5 × 105 schizonts of each line), and a synchronous infec-
tion allowed to establish. 2  µl of blood were extracted 
bi-hourly within the first 28 h post-schizont injection via 
tail vein puncture, lysed in 20 µl of 1 × PLB, and imaged. 
For maximum sensitivity of single blood stages, a 1:50 
dilution of NanoGlo™ luciferase assay substrate was used. 
In all other assays for in vivo parasitaemia measurements, 
a 1:250 dilution was used. Erythrocytes from uninfected 
mice were used as negative controls.
Statistical analyses
All data analysis of luminescence values was performed 
using the LivingImage 4.1 software. Analyses for Pear-
son correlation coefficients, Student’s t tests, and linear 
regressions were carried out using STATA 13.0 software. 
Other than the STATA-generated graphics, all other 
graphics were generated using the Prism 6.0 software. All 
parasite measurements including diameter, radius, and 
area, were performed using plugins freely available in Fiji. 
Significance in all assays was determined upon p values 
being equal to, or less than 0.05.
Results
PbNLuc parasite generation and clone selection
For the generation of the pNLuc plasmid, the GFP cod-
ing sequence from the pL0017 plasmid was excised, 
and replaced by the NanoLuc coding sequence, thereby 
allowing expression of NanoLuc under the control of 
the ef1α promoter. PbmCherryHsp70 parasites [98] were 
transfected with the pNLuc construct, and this resulted 
in single cross-over integration events. Individual Pb 
mCherryHsp70NLucef1α clones were isolated by detached 
cell injection (89) into six mice. A drop of blood was iso-
lated from all mice harbouring synchronous ring infec-
tions. Parasites were probed with NanoGlo™ according 
to manufacturer’s instructions, and luminescence meas-
ured with an IVIS Lumina II imager. Measurements were 
repeated three times at different days post-infection, 
isolating equal numbers of iRBCs by dilution. Although 
signal intensity between most clones did not differ sig-
nificantly, the clone that consistently showed the highest 
signal was chosen for downstream analyses.
Bioluminescence‑based analysis of PbNLuc oocysts on the 
mosquito midgut
Microscopy-based imaging and quantification of Pbm-
CherryHsp70, PbmCherryHsp70FLucef1α [39] (henceforth 
referred to as PbFluc) and PbmCherryHsp70NLucef1α 
(henceforth referred to as PbNLuc) in mosquito mid-
guts showed that all three lines strongly express mCherry 
(Fig. 2a) (Diagram adapted from [102]) and have equiva-
lent average numbers of oocysts per mosquito on days 
7–9 post-feed (Fig. 2b). For comparison of PbNLuc and 
PbFLuc luminescence intensities, ten pools of five mid-
guts with approximately equal numbers of oocysts from 
PbFLuc- and PbNLuc-infected mosquitoes were dis-
sected, lysed, and their bioluminescence measured. 
Midguts infected with PbNLuc oocysts showed 160- to 
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180-fold higher signal (p  <  0.05) than midguts infected 
with PbFLuc oocysts (Fig. 2c).
In order to determine the NanoLuc assay’s sensitiv-
ity in detecting changes in average numbers and sizes of 
oocysts throughout their development on midguts, 50 
midguts from mosquitoes in three independent cages 
were dissected and measured at days 7–9 and 15 post-
feed. Although detecting small variations (in the range 
of tens of oocysts) is challenging using firefly luciferase, 
NanoLuc-based luminescence in PbNLuc parasites 
allowed detection of a clear progressive increase in inten-
sity from days 7–9 post-feed, which decreased again at 
day 15 coinciding with sporozoite egress and migration 
to the salivary glands (Fig. 2d).
As proof of principle for the use of PbNLuc in assess-
ment of infection prevalence in mosquitoes, a total of 
200 mosquitoes were sorted by fluorescence into two 
groups consisting either of mCherry-positive (infected), 
or mCherry-negative (non-infected) mosquitoes. By 
microscopy alone, the prevalence of infection was cal-
culated to be 70 % (SD, 10.5 %). These mosquitoes were 
then dissected and their midguts imaged by biolumines-
cence. The prevalence estimate detected by luminescence 
of this same group, was 88 % (SD, 12 %) (Fig. 2e), empha-
sizing the enhanced sensitivity of the assay for determin-
ing presence or absence of midgut oocysts by NanoLuc 
luminescence rather than fluorescence. In addition, 
the assay avoids observer bias in terms of assessment 
of fluorescence at low oocyst densities. While fluores-
cence-based sorting is to an extent subjective, sensitive 
bioluminescence imaging enables non-subjective, quanti-
tative assessment of infection prevalence.
Having proven the enhanced sensitivity of PbNLuc over 
fluorescence for assessment of prevalence, a next step 
was to explore the correlation of PbNLuc luminescence 
with oocyst numbers in individual midguts. At days 7–9 
post-feed, 100 infected midguts of PbFLuc or PbNLuc-
infected mosquitoes were dissected, imaged by fluo-
rescence for manual or semi-automated quantification 
of oocysts, and then immediately lysed for imaging by 
luminescence. Oocyst numbers were quantified by two 
different methods, namely, a previously published semi-
quantitative method based on fluorescence [103]; and 
light emission values based on NanoLuc or firefly lucif-
erase bioluminescence. Figure  2f, g show fitted correla-
tions and 95  % confidence intervals of bioluminescence 
versus automated fluorescence counts (each dot corre-
sponds to the measurement of one individual midgut). 
PbNLuc shows a Pearson correlation coefficient of 0.74 
(Fig.  2f ), while PbFLuc shows a correlation coefficient 
of 0.61 (Fig. 2g). This suggests that the increased bright-
ness of NanoLuc luciferase in PbNLuc parasites results 
in more sensitive measurements, allowing differences 
of even ten to a hundred oocysts to be distinguished. 
Nevertheless, a perfect correlation between counts and 
luminescence is not expected, as individual oocysts may 
greatly vary in their sporozoite load. This phenomenon 
has previously been reported in luminescence-based 
assays for transmission assessment [50].
Bioluminescence‑based analysis of PbNLuc sporozoites 
and limit of detection in vitro
In the Plasmodium life cycle, a critical step following 
oocyst formation is the production of sporozoites, as 
these latter forms ultimately enable mosquito-to-human 
transmission. Having explored the suitability and sensi-
tivity of PbNLuc to assess oocyst formation and devel-
opment, this section explores the sensitivity and limit of 
detection of PbNLuc to quantify sporozoites. Fluores-
cence-based images of sporozoites within salivary glands 
of mosquitoes infected with PbFLuc or PbNLuc were 
obtained (Fig. 3a) (Diagram adapted from [102]), and the 
number of sporozoites in both luminescent lines were 
quantified at days 16, 18, 20, 22, 24, 26 and 28 days post-
feed. PbFLuc and PbNLuc show equivalent sporozoite 
counts at all days post-feed, with maximum sporozoite 
loads detected between days 20 and 24 post-feed (Fig. 3b) 
suggesting no differences in egress and development 
(See figure on previous page.) 
Fig. 2 Bioluminescence imaging of oocysts in mosquito midguts. a Representative fluorescence images of dissected midguts from PbmCherry, 
PbFLuc, and PbNLuc-infected mosquitoes. b Average oocyst numbers in PbmCherry, PbFLuc and PbNLuc-infected midguts at days 7–9 post-feed. c 
Luminescence ratio obtained from 50 mosquitoes infected with PbFLuc or PbNLuc lines (PbFLuc set as 1). d Comparative analysis of prevalence of 
PbNLuc infection in mosquitoes. Luminescence values of PbNLuc-infected mosquitoes at days 7–9 post-feed, prior to oocyst rupture and sporozoite 
egress, and at day 15 post-feed, following initial sporozoite egress events. e At day 9 post-feed, 200 mosquitoes were sorted by fluorescence into 
‘infected’ and ‘uninfected’. Based on these data, the prevalence of infection was calculated. The same mosquitoes were dissected and the midguts 
lysed for bioluminescence assays and infection prevalence calculation. f Scatter plot showing correlation and 95 % confidence interval range (CI) of 
PbNLuc bioluminescence values to fluorescence-based semi-automated counts. 100 individual PbNLuc-infected mosquitoes (represented by each 
dot) were dissected, and their midguts extracted. Oocyst numbers for each individual midgut were quantified using a semi-automated fluorescence-
based macro (y-axis). Midguts were then lysed and imaged by luminescence (x-axis). g Scatter plot showing correlation and 95 % CI range of PbFLuc 
bioluminescence values to fluorescence-based semi-automated counts. Experimental setup as described for (f). [Graphs are the result of triplicate 
experiments. Luminescence values are expressed as photons per second (p/s); *p < 0.05; ***p < 0.001; error bars in graphs represent standard devia-
tions (SD)]
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between the two parasite lines. Next, equal numbers of 
PbFLuc and PbNLuc sporozoites (four separate pools of 
50,000) were lysed, and their luminescence measured for 
comparison of their luminescence intensities. Lumines-
cence values of PbNLuc sporozoites were 170-fold higher 
than luminescence values for equal numbers of PbFLuc 
sporozoites (Fig. 3c), confirming the results presented in 
Fig. 2c. To determine the detection limit of NanoLuc for 
sporozoites, serial dilutions of PbNLuc sporozoites were 
generated in triplicate, and lysed for measurement. While 
the minimum number of detectable PbFLuc sporozo-
ites was between the range of 50 and 100, single PbN-
Luc sporozoites were detectable (subject to a sporozoite 
actually being present in the well) (Fig. 3d, e). The reason 
why 5 parasites per well are presented was the experi-
mental setup itself: using serial dilutions, the probability 
of one single sporozoite being present in each well was 
10 %. Nevertheless, every time there was a single sporo-
zoite per well, signal was detected. Sporozoite numbers 
showed high correlation values with the log values of 
luminescence (R2  =  0.913 for PbNLuc, and R2  =  0.921 
for PbFLuc) (Fig.  3d). This highly significant correlation 
shows the success of the assay in terms of both detection 
of very low sporozoite densities, and detection of small 
variations in sporozoite numbers. The detection limit of 
PbNLuc, however, is higher than that of PbFLuc. As a 
proof of principle for its application, salivary glands of 
100 PbNLuc-infected mosquitoes were dissected, and 
the correlation between sporozoite numbers (as assessed 
by manual counting) and luminescence was calculated. 
Each dot represents the sporozoites of a single mosquito, 
as assessed by luminescence (x-axis) and manual counts 
(y-axis). On one hand, the test confirmed a high corre-
lation between sporozoite numbers and luminescence 
values (R2  =  0.95) when applied to single mosquitoes 
(Fig.  3f ). On the other hand, the assay also shows that 
given this high correlation, visual inspection of plates to 
estimate variability in the overall burden of sporozoites 
per mosquito is possible (Fig. 3g).
Bioluminescence‑based analysis of PbNLuc liver stages 
and limit of detection in vitro
Having proven the use and sensitivity of NanoLuc in 
mosquito stages, next liver stages of infection were 
assessed in  vivo and in  vitro. HepG2 cells seeded in 24 
well-plates were infected with 10,000 PbNLuc sporozo-
ites per well, and imaged by fluorescence microscopy at 
6, 12, 24, 36, 48 and 56  h post-infection (Fig.  4a shows 
representative images and a schematic (adapted from 
[104]) of liver stage development). To exclude differences 
in luminescence due to differences in overall develop-
ment or sizes, PbmCherry, PbFLuc and PbNLuc parasite 
sizes were measured at 6, 12, 24, 36, 48 and 56  h post-
infection, and infection success and survival (i.e. total 
number of HepG2 cells infected at each time point) were 
quantified by fluorescence. No differences were detected 
between PbmCherry, PbFLuc and PbNLuc, neither 
in terms of size, nor successful liver stage completion 
(detached cell formation).
In order to compare luminescence intensities of 
PbFLuc and PbNLuc, HepG2 cells in 6 wells of a 24-well 
plate were infected with an equal number of sporozoites 
of either one of the strains. At 40 h post-infection these 
cells were lysed and their luminescence quantified. PbN-
Luc showed 140-fold higher luminescence than PbFLuc 
(Fig. 4b). Next, in order to determine the detection limit 
for liver stages, PbNLuc-infected HepG2 cells were 
detached, total parasite numbers estimated, and serial 
dilutions generated for each time post-infection, ranging 
from 1 to 1000 parasites for each time point (i.e., 6, 12, 
24, 36, 48 and 56  h post-infection). The assay was suc-
cessful in detection of single liver stage parasites at all 
(See figure on previous page.) 
Fig. 3 Bioluminescence imaging of sporozoites in mosquito salivary glands. a Representative images obtained by fluorescence microscopy, of 
dissected salivary glands from PbFLuc, and PbNLuc-infected mosquitoes. b Average sporozoite numbers per mosquito at days 16–28 post-feed, in 
groups of PbFLuc and PbNLuc-infected mosquitoes. c Luminescence ratio of PbFLuc and PbNLuc sporozoites. Four sets of 50,000 sporozoites from 
10 separate mosquitoes each, for either PbFLuc or PbNLuc, were isolated from the salivary glands, and their luminescence acquired. The value for 
PbFLuc luminescence was set to a value of 1, and the value of PbNLuc luminescence expressed in relation to the PbFLuc value. d Correlation of 
luminescence values of PbNLuc and PbFLuc, and detection limit obtained by imaging 1–106 sporozoites (Square at axis shows no signal from PbFLuc 
at low sporozoite densities). 20 independent mosquitoes were dissected, and their sporozoites diluted to the specific values shown in the figure. 
R2 corresponds to values over the detection limit of each respective parasite line. e Images from 3 independent dilutions of sporozoites (obtained 
from pools of 20 independent mosquitoes each). Measurements of different sporozoite concentrations were made in separate plates to avoid 
under-detection, or signal saturation in the presence of extremely high luminescence values. f Scatter plot showing correlation and 95 % CI range of 
PbNLuc luminescence values of 100 individual mosquitoes to manual counts in a Neubauer chamber. 100 individual PbNLuc-infected mosquitoes 
(represented by each dot) were dissected, and their salivary glands extracted. Sporozoite numbers for each individual mosquito dissected were 
quantified manually using a Neubauer chamber (y-axis). Sporozoites were then lysed and imaged by luminescence (x-axis). g Representative IVIS 
image of individual dissected and disrupted salivary glands (salivary glands from one uninfected mosquito is used as control in every row) Blue and 
red outlines show, respectively, minimum and maximum detected sporozoite loads. (luminescence values are expressed as photons per second (p/s) 
(linear or logarithmic) [***p < 0.001; error bars in all graphs represent standard deviations (SD)]
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times post-infection, and enabled differences (Fig. 4c) in 
the range of tens to hundreds to be detected. This level of 
sensitivity has not been reported for firefly luciferase, nor 
was it ascertained in the present work.
Next, kinetics of liver stage infection in vitro through-
out pre-erythrocytic development in terms of growth 
and survival, were determined by luminescence (Fig. 4d). 
HepG2 cells were infected with an initial inoculum of 
10,000 sporozoites per well. Fluorescence images of 
at least 100 infected cells per time point were acquired 
for size measurement. Ten wells of a 24 well-plate were 
assessed by fluorescence imaging for quantification of 
parasites for each time point (shown in Fig.  4e). Finally 
cells were lysed at 6, 12, 24, 36, 48 and 56 h post-infec-
tion, and bioluminescence measured (Fig.  4f ). Each 
time point was repeated in 10 wells in three independ-
ent experiments. Total parasite sizes and numbers at 
6 h post-infection were set as 100  % (Fig.  4e, f ). While 
parasite numbers decreased significantly already at 12 h 
post-infection (50  % reduction), a dramatic decrease in 
numbers (of about 80 % compared to 6 h post-infection) 
was observed at 24  h post-infection. Parasite number 
remained relatively constant at from 24 to 36 and 48  h, 
and showed only a 2  % further decrease at 56  h post-
infection, potentially explained by a small number of 
detached cells occurring at this relatively early egress 
time point (Fig. 4e, black line). Conversely, parasite sizes 
at 6 and 12 h post-infection were almost equal, while size 
increased 3-, 6-, and 10-fold at 24, 36 and 48  h respec-
tively, compared to parasite sizes at 6  h post-infection. 
The parasite size increase between 48 and 56 h was only 
minimal (Fig.  4e, blue line). The overall result of these 
changes in parasite numbers and sizes, in addition to 
potential changes in promoter activity, resulted in varia-
tions in luminescence intensity through time, with total 
luminescence being lowest at 24  h post-infection, after 
which these values increased by 48 h to almost 300 % of 
the level measured at 6 h post-infection (Fig. 4f ).
Bioluminescence‑based analysis of PbNLuc liver egress 
in vitro by assessment of detached cells and merozoite 
counts
While it was possible to investigate overall liver stage 
growth of PbNLuc parasites by bioluminescence, a 
marker of fully successful liver stage development is the 
successful production of merosomes and detached cells 
in  vitro. Detached cell formation in  vitro, like mero-
some formation and parasite egress from the liver in vivo, 
occurs upon formation of merozoites [101]. Therefore 
whether a PbNLuc-based luminescence is sensitive 
enough to allow estimation of numbers of merozoites in 
individual detached cells, was investigated next. While 
individual merozoites were not quantified, their number 
was estimated by measuring the detached cell volume 
as previously published [101], and as shown in Fig.  5a. 
Figure  5b shows representative bioluminescence images 
of individual detached cells of various sizes (and there-
fore, different numbers of merozoites). Each well has a 
single detached cell. While the median calculated num-
ber of merozoites in 100 detached cells was 4500 (with 
the average detached cell volume being 11,780  μm3), 
Fig.  5b shows clear outliers (marked) representing both 
larger detached cells or those with much higher mero-
zoite numbers (marked in red outline), and also those 
extremely small or with very reduced merozoite num-
bers (marked in blue outline). Figure  5c shows repre-
sentative fluorescence images of these extreme size 
variations between merosomes (M) and large detached 
cells (L-DC). Figure 5d shows the correlation of detached 
cell luminescence with the volume calculated by fluores-
cence imaging, and the number of merozoites calculated 
on the basis of the volume estimated.
Liver egress and determination of pre‑patency period
Given the high sensitivity of NanoLuc detection, liver 
stage egress in  vivo was re-investigated. While the most 
sensitive assay reported to date states that the first 
(See figure on previous page.)  
Fig. 4 Bioluminescence imaging of P. berghei pre-erythrocytic stages. a Fluoresence images of liver cells infected with PbNLuc, showing parasite 
development from 2 h to egress. Scale bar is equal to 15 μm. The lower panel shows a schematic representation of liver stage development at the 
corresponding time points. b Ratio of luminescence between PbFLuc and PbNLuc signal arising from 6 independent sets of HepG2 cells infected 
with 10,000 sporozoites each, and lysed at 40 h post-infection. The value for PbFLuc luminescence was set to a value of 1, and the value of PbNLuc 
luminescence expressed in relation to the PbFLuc value. c Curve of serial dilutions of parasites (1–1000) at 12, 24, 36, 48 and 56 h of development in 
HepG2 cells. Six sets of 30,000 HepG2 cells were infected with 5000 sporozoites. Parasite numbers were calculated based on mCherry fluorescence, 
and total parasite load per well calculated. Cells were detached at each indicated time post-infection, and diluted to each indicated values.  
d Representative IVIS image of luminescence following the kinetics of infection at 12, 24, 36, 48 and 56 h post-infection following infection of HepG2 
cells with an initial inoculum of 10,000 sporozoites. e Curve showing kinetics based on fluorescence measurements of total numbers, and sizes of at 
least 300 parasites at 6, 12, 24, 36, 48 and 56 h post-infection. e, f Represent the fluorescence-based quantification of (d). Parasite sizes (areas, μm2) 
were calculated based on acquired fluorescence images. f Curve showing kinetics of luminescence alone, corresponding to cells measured in (e) 
[luminescence measured in photons per second (p/s); ***p < 0.001; error bars in all graphs represent standard deviations (SD)]
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Fig. 5 NanoLuc imaging of P. berghei detached cells allows calculation of merozoite numbers. a Schematic representation of a detached cell. The 
calculation of merozoite numbers within a detached cell is derived from measurement of the detached cell volume. b Representative biolumines-
cent image of 64 individual detached cells. c Fluorescence images of 2 types of detached cell accounting for variability in luminescent measure-
ments. The top panel shows a merosome (M) with even distribution of merozoites within the cell body. The bottom panel shows a large detached 
cell (L-DC) with even distribution of merozoites within the cell body. Scale bar corresponds to 10 μm. d Scatter plot showing significant correlation 
of detached cell volumes and merozoite numbers (y-axis), with and PbNLuc luminescence (x-axis). 100 individual detached cells symbolizing suc-
cessful completion of PbNLuc liver infections (represented by each dot) were detected by mCherry-based fluorescence microscopy, imaged, and 
then individually captured and lysed for luminescence imaging. The radius of the detached cell was measured, and the volume of the detached cell 
thereby estimated as described in (a) [luminescence measured in photons per second (p/s)]
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hepatocyte-derived blood stage parasites can be detected 
earliest at 60  h post-sporozoite injection [15], previ-
ously reported in  vivo luminescence assays [39], as well 
as in  vivo measurements performed here using PbFLuc 
(Fig.  6a) suggested a significant decrease in liver loads 
from 42 h post-infection onwards in untreated mice. This 
suggests that egress has potentially already begun occur-
ring at this time point. Whether the previously reported 
lack of detection of parasites in peripheral blood between 
42 and 60 h post-sporozoite injection is due to very low 
parasite densities (and therefore undetectable by firefly 
luciferase), or due to migration of merosomes to specific 
tissues (away from the periphery), was not known. Fol-
lowing infection of C57BL/6 (permissive) and Balb/c 
(refractive) mice with 5000 PbNLuc sporozoites, lumi-
nescence in peripheral blood was measured at 12, 24, 
30 h post-infection, and every 4 from 36 h post-infection 
onwards, until 70  h post-infection. Using the maximum 
sensitivity setup for NanoLuc, luminescence signal was 
detected from 36  h post-infection in some mice, and by 
40  h post-infection and at all subsequent time points, 
in all mice. Consistent with the known permissiveness 
of C57BL/6 mice for liver stages, and the refractoriness 
associated with liver stage infections in Balb/c mice, the 
detectable levels of luminescence in peripheral blood were 
on average 100-fold lower in Balb/c mice, but nevertheless 
the earliest signal suggesting egress, occurred at 36  h in 
both mouse strains (Fig. 6b). In parallel to PbNLuc infec-
tions, a separate group of C57BL/6 mice was infected with 
PbFLuc. As published in previous work [15], firefly-lucif-
erase parasites were only detected at 60 h post-infection, 
but not earlier (Fig. 6c). Dynamics of egress displayed by 
PbNLuc and PbFLuc are shown in Fig. 6c.
In order to determine whether parasites (merosomes, 
free merozoites or early infected RBCs) present in 
peripheral blood from 36  h onwards were infectious to 
naïve mice thereby confirming egress, 20 μl of blood were 
extracted from the sporozoite-infected C57BL/6 mice at 
36, 40, 42, 44, 52, 56 and 60 h post-infection, and injected 
intravenously into three naive C57BL/6 mice for each 
time point. While blood extracted at 36, 40 and 42 h did 
not lead to blood stage infections in the naïve mice, blood 
extracted at 44, 52, 56 and 60  h resulted in infection in 
all three recipient mice (Fig. 6d). Careful analysis by fluo-
rescence microscopy allowed observation of amorphous, 
relatively large structures (potentially merosomes) at 36 
to 42 h post-infection, which nevertheless did not lead to 
infection in the recipient mice.
Next it was determined whether differences exist in 
egress times of PbNLuc parasites in mice injected with 
sporozoites by intravenous injection, or mice on which 
infected mosquitoes fed. No differences in egress times 
were observed, despite mice infected by intravenous 
injection of 5000 sporozoites displaying at least tenfold 
higher signal than mice infected by feeds with five mos-
quitoes (Fig. 6e).
Bioluminescence‑based analysis of PbNLuc blood stages, 
and limit of detection
As for other stages, the sensitivity of NanoLuc for low 
parasite densities was tested in blood stages of infec-
tion with PbNLuc. Limiting dilution ranging from 1 to 
10,000 parasites showed that even single parasites can be 
detected, and that parasite number and luminescence are 
highly correlated (R2 = 0.956) (Fig. 7a). While infections 
with PbFLuc hold equally high correlation (R2 = 0.921), 
its signal intensity is at least 100-fold lower, and does 
not allow detection of single parasites (Fig. 7a). To deter-
mine differences in sensitivity of PbNLuc compared to 
PbFLuc in blood stage infections, a drop of blood was 
obtained by tail vein puncture, and 1000 parasites were 
isolated by dilution in 1xPBS. Figure 7b shows that PbN-
Luc has 150-fold higher signal than PbFLuc, supporting 
the results with the other parasite stages. To determine 
whether differences in parasite development exist in 
Balb/c and C57BL/6 mice, parasitaemias arising from 
infection with 106 schizonts by tail-vein injection were 
followed by luminescence and Giemsa stains for 7 days. 
No significant differences concerning blood stage infec-
tion were found between the two mouse strains (Fig. 7c, 
d). Figure 7c shows representative images from 5 differ-
ent mice at days 1–4 post-infection.
While assessment of various sequential parasite dilu-
tions (Fig.  7a) showed high correlation with lumines-
cence, whether in  vivo parasitemia correlates with 
luminescence was further explored. Figure 7e shows the 
correlation of luminescence with parasitaemia calcula-
tions assessed by manual counting of Giemsa-stained 
thin blood smears. Parasitaemia and luminescence values 
showed a strong correlation (R2 = 0.907) (Fig. 7e).
The sensitivity of the NanoLuc assay allows determi-
nation and comparison of multiplication rates between 
mice and parasite strains. Previous work has explored 
the use of luminescence to detect schizont sequestration 
in synchronous infections in relation to the day light-
cycle [16, 17]. In this work, blood stage parasites from a 
donor mouse were cultured in order to purify schizonts. 
Schizonts were injected into naïve mice to establish syn-
chronous infections that were followed bi-hourly over 
27 h, when specific times would correspond to synchro-
nous ring, trophozoite, and schizont stages. Figure  7f 
shows results of these bi-hourly luminescence measure-
ments of peripheral blood parasitaemia of mice infected 
with PbNLuc schizonts. The drop in parasitaemia from 
18 h onwards, coinciding with the beginning of schizont 
sequestration in the vasculature, is clearly identified.
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In order to test the use of PbNLuc in multiplex assays 
using two different luciferases, mice were co-infected 
with PbNLuc and PbFLuc. Figure  7g shows the com-
parative values of luminescence of both luciferases in 
the same mice, clearly showing sequestration of schiz-
onts from both strains at around 18 h after synchronous 
infection.
Finally, to test further potential applications of the 
NanoLuc-expressing parasites, since even single PbNLuc 
parasites can be identified due to the strong luminescence 
intensity of NanoLuc, and limiting dilution is a routinely 
used method for clonal selection of genetically-modified 
parasites, it was determined whether identification of 
single parasites expressing NanoLuc, followed by their 
injection into naïve mice could lead to effective infection. 
By limiting dilution, the estimated volume containing 1 
parasite was isolated and deposited into a 96-well plate. 
NanoLuc was diluted in 1 × PBS rather than lysis buffer 
to ensure the viability of the parasites, and 4 of the 96 (i.e. 
5 %) wells were found to be positive (Fig. 7h). The full vol-
ume of all four wells was isolated and injected into recipi-
ent mice. All caused effective infections in the recipient 
animals, suggesting the usefulness of the method to avoid 
large animal usage in limiting dilution experiments.
Discussion
Plasmodium luminescent lines have been widely used 
to study parasite biology in  vivo and in  vitro, for appli-
cations ranging from evaluation of the effect of anti-
malarial compounds to characterization of parasites 
with mutations affecting one or various stages of the life 
cycle. While firefly luciferase has been successfully and 
widely used for in vivo and in vitro applications, the novel 
enzyme NanoLuc has been reported to produce 150-
fold higher luminescence intensities than firefly lucif-
erase [70], making it an attractive tool for highly sensitive 
characterization of all P. berghei stages in the context of 
mutations, drug-treatments and as yet understudied 
phenomena such as parasite egress from the host liver. 
In this work, NanoLuc was found to be highly sensitive 
for detection of parasite densities down to single sporo-
zoites, single liver stages in  vitro, and single infected 
erythrocytes, and highly accurate in determination of 
overall parasite loads at all infection stages. Such sensitiv-
ity and accuracy has not previously been reported with 
the widely used firefly luciferase. While various muta-
tions in the P. berghei genome produce drastic changes 
in terms of development or growth rates, others pro-
duce only mild effects that cannot be assessed without 
extremely sensitive tools. The benefits and applications 
(See figure on next page.) 
Fig. 7 Bioluminescence imaging of P. berghei blood stages. a Luminescence values from various concentrations of iRBCs from PbNLuc- and PbFluc-
infected mice, ranging from 1 to 10,000 iRBCs (values shown in logarithmic scale). b Ratio of luminescence of PbNLuc iRBCs compared to PbFLuc 
iRBCs showing a 150-fold higher signal. 1000 parasites were isolated from a drop of blood of synchronously infected mice at 18 h post-infection. 
The value for PbFLuc luminescence was set to a value of 1, and the value of PbNLuc luminescence expressed in relation to the PbFLuc value. c, d 
Parasitaemia curve as measured by bioluminescence, in Balb/c and C57BL/6 mice. 9 Balb/c and C57BL/6 mice were infected with 105 parasites, and 
their parasitaemia followed daily. At every time post-infection, 20μl of blood were taken by tail vein puncture, and luminescence was assessed; c 
shows representative images of 5 mice followed in (d). e Correlation between parasitaemia and luminescence at various times post-infection and 
various parasite burdens. Following injection of 105 parasites into mice, 25 μl of blood were obtained by tail vein puncture for measurement either by 
luminescence (x-axis) or Giemsa stain of thin blood smears from which parasitaemia was quantified using a light microscope (y-axis). f Biolumines-
cence signal from PbNLuc synchronous infections. 106 schizonts were injected into C57BL/6 mice, and 20 μl of blood collected bi-hourly from 9 to 
27 h post-infection, showing sequestration from 18 to 25 h post-infection. g Bioluminescence signal from blood of PbNLuc and PbFLuc co-infected 
mice, as measured bi-hourly from 9 to 27 h post-synchronous infections, showing marked schizont sequestration of both parasite lines from 18 to 
25 h. h Graphical representation of a limiting dilution leading to isolation of single parasites. The graph shows 5.5 % positivity. [***p < 0.001; error bars 
in all graphs represent standard deviations (SD)]
(See figure on previous page.)  
Fig. 6 Bioluminescence imaging of P. berghei liver stage egress. a Luminescence values obtained from in vivo imaging of C57BL/6 mice infected with 
5000 sporozoites of PbFLuc. Dotted line shows the peak of luminescence after which the first obvious decrease in signal from the mouse liver in vivo 
after around 48 h occurs. b Egress measured by first appearance of parasites in the periphery. 2 μl of blood were obtained via tail vein puncture and 
lysed in 20 μl of 1 × PLB for bioluminescence measurement. Luminescence values of peripheral blood from C57BL/6 and Balb/c mice infected with 
5000 PbNLuc sporozoites obtained at the indicated time points post-sporozoite injection until 70 h, showing the kinetics of egress as measured 
by PbNLuc. c Representative luminescence-based assay of egress at the indicated time points in 4 separate C57BL/6 and Balb/c mice. 2 μl of blood 
were obtained via tail vein puncture and lysed in 20 μl of 1 × PLB for bioluminescence measurement. While egress of PbNLuc is detected earliest at 
36 h post-infection, egress of PbFLuc is detected for the first time at 60 h post-infection. d Success of passages of liver-egressed parasites from 36 h 
onwards into naïve mice. Six C57BL/6 mice were infected with 5000 sporozoites each, and at 36, 40, 42 44, 52, 56 and 60 h post-sporozoite injection, 
20 μl of blood removed, diluted in 200 μl of 1 × PBS and the 220 μl intravenously injected into 3 naïve mice. It was later (at 70–90 h post-infection) 
assessed whether the inoculum had produced an infection in these recipient mice. e Comparative kinetics of egress as measured by luminescence in 
the blood, in mice infected by intravenous injection of 5000 sporozoites, or by mosquito feeds (5 mosquitoes) [luminescence measured in photons 
per second (p/s); ***p < 0.001; error bars in all graphs represent standard deviations (SD)]
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of the PbNLuc transgenic line for the characterization of 
anti-malarial drugs and mutant parasites is discussed for 
each stage below in the context of the findings presented 
in this work.
Malaria transmission is a major focus of research as 
a target for anti-malarial interventions. Evaluation of 
Plasmodium oocyst burden in the midguts of Anoph-
eles mosquitoes is one of the most important methods 
for investigating transmission. Most reported assays 
rely on manual counting of fluorescent oocysts, which 
is slow and error-prone given the complex organization 
and fluorescent background noise in the mosquito mid-
guts. This challenge limits the scalability and throughput 
of the assay in general. In 2012, Delves and Sinden pre-
sented a semi-automated method for counting fluores-
cent oocysts that significantly increases the scalability 
and reduces evaluation times [103]. In this work, a com-
parison of PbNLuc sensitivity both with manual counts 
and the semi-automated fluorescence-based method was 
undertaken. A medium correlation between both meth-
ods was found, with PbNLuc producing a varied range of 
light output for the same hypothetical number of oocysts 
calculated by the semi-automated fluorescence-based 
method. Two reasons might contribute to this discrep-
ancy: the inevitable variation in productivity of oocysts, 
and on the other hand, the high sensitivity of the Nano-
Glo™ assay detecting parasites that are not easily detect-
able by fluorescence microscopy. Although NanoLuc 
assays are slightly limited in the accuracy of quantita-
tively determining oocyst numbers, the assay gives a clear 
idea of the overall burden in the mosquito midgut. Firefly 
luciferase-expressing P. falciparum parasites have been 
generated in the context of transmission-reducing assays 
(TRAs) or transmission-blocking assays, and showed 
that luciferase-based TRA estimates, consistently mirror 
those based on microscopy read-outs [50, 105]. Given the 
higher sensitivity of PbNLuc, it is envisaged that upon 
generation of a marker-free parasite line, this tool will 
enable much more accurate calculation of the transmis-
sion-reducing or -blocking effects of drugs and genetic 
mutations in P. berghei knock-outs. In the context of 
calculating infection prevalence among mosquito pools, 
NanoLuc showed greater sensitivity than observer-based 
determination of fluorescence in the midguts, in particu-
lar if oocyst burdens were low. The sensitivity of the assay 
further allowed assessment of changes in oocyst size, 
maturation, and assumingly, promoter activity, between 
days 7 and 9 post-infection, showing that interventions 
or mutations producing even slight effects and not abro-
gation, as well as effects in sporogonic development, can 
still be evaluated with this method.
While the correlation of oocyst counts with lumi-
nescence values is somewhat limited by confounders 
including oocyst sizes in the midguts, sporozoite quan-
tification and correlation with luminescence is straight-
forward. PbNLuc allowed detection of between 1 and 
10 sporozoites, with a sensitivity not achieved by the 
PbFLuc counterparts. Equally in the context of transmis-
sion-blocking research, the assay can accurately quantify 
even slight variations in sporozoite burden among a mos-
quito population. Preliminary analyses are being under-
taken to characterize the effect of treatment of mice with 
atovaquone, chloroquine and sulfadiazine (prior to mos-
quito feeds) on PbNLuc oocyst and sporozoite formation 
as measured by luminescence. These and other additional 
data will be published separately.
Aside from its applicability in the context of transmis-
sion-blocking drugs, PbNLuc is a promising line for the 
careful characterization of events occurring in the game-
tocyte-ookinete-oocyst transition, as well as the kinetics 
of sporozoite development, egress, and migration to the 
mosquito salivary glands. So far, Plasmodium mutants 
have been generated to characterize the role of multiple 
proteins involved in mosquito-stage development. Exam-
ples of targeted proteins found to play a role in mosquito-
stage Plasmodium development include, among others, 
those necessary for gamete release prior to the produc-
tion of ookinetes; those necessary for ookinete formation 
and escape from the midgut and those involved in sporo-
zoite egress, migration and motility. Characterization of 
the kinetics of Plasmodium mosquito stage development 
have so far largely relied on fluorescence-based micros-
copy, and only later on firefly bioluminescence imaging. 
The high bioluminescent signal of NanoLuc would enable 
much more sensitive evaluation of phenotypes of mutant 
Plasmodium parasites, potentially allowing identification 
of modifications leading to even relatively mild pheno-
types. The phenotypes potentially measurable by PbNLuc 
include developmental arrest within the mosquito; defi-
cient ookinete formation; deficient or abrogated oocyst 
formation; deficient sporozoite egress, and overall reduc-
tions in parasite loads at oocyst and sporozoite stages.
A further application where PbNLuc would be advan-
tageous is in exploring the dynamics of P. berghei trans-
mission from mosquitoes to mice at the skin interface. 
Transmission dynamics have previously been assessed by 
approaches such as quantification of sporozoites released 
by mosquitoes into liquid media or glass slides [106], or 
determination of sporozoite 18S rRNA [107], or beta-
galactosidase [108] expressed in transgenic sporozoites 
following mosquito feeding on mouse skin. Since then, 
complex microscopic approaches have been developed, 
including the use of intravital and spinning disc micros-
copy [109]. While these provide accurate measurements 
of sporozoite dynamics, NanoLuc offers the possibility of 
assessing sporozoite localization in, and time of clearance 
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from, the host skin, which would be advantageous in the 
context of host and parasite mutations affecting sporozo-
ite motility, immune defence, or skin traversal. While lim-
itations for the use of NanoLuc in in vivo imaging of deep 
organs will be discussed below, the use of this enzyme in 
the skin and respiratory tract has been reported for other 
organisms, with rather successful results [73, 78].
Following injection into the host skin, and upon reach-
ing the host liver, each Plasmodium sporozoite is able to 
asexually replicate within host hepatocytes resulting in 
the production of thousands of erythrocyte-infectious 
merozoites. The liver stage, although clinically silent, is 
a bottleneck for parasite development, hence ideal for 
anti-malarial interventions. In the context of liver stage 
infections in  vitro, NanoLuc showed great sensitivity, 
detecting as little as one parasite in all pre-erythrocytic 
developmental stages investigated. While fluorescence 
microscopy has been extremely valuable for the care-
ful dissection of mechanisms altered upon mutations, or 
drug treatment affecting either the parasite or the host [8, 
11, 15, 34–37, 39, 40, 51], luminescence imaging provides 
a quick and sensitive alternative to measuring overall 
effects of drugs and mutations on parasite development, 
host-pathogen interactions, parasite survival, and suc-
cessful completion of the pre-erythrocytic stage. A rela-
tive limitation of this assay in  vitro, is that it does not 
allow differentiation between parasite numbers and sizes, 
but rather gives only a value of luminescence which can 
be confounded by the effects of promoter activity. Never-
theless, the assay is highly sensitive in showing the over-
all kinetics of liver stage development from sporozoite 
injection to merosome formation. In the present work, it 
enabled visualization of major drops in luminescent sig-
nal early on in infection, corresponding to a decrease in 
parasite numbers (not sizes). This is consistent with the 
fact that a massive number of parasites are eliminated by 
host cell autophagy, prior to 24 h post-hepatocyte inva-
sion [39]. Following this elimination, surviving parasites 
will be able to develop normally with little losses in the 
subsequent hours preceding liver stage egress.
Mutations or drugs affecting the parasite, includ-
ing sporozoite invasion, sporozoite motility, liver stage 
growth, host immune mechanisms, establishment of 
a parasitophorous vacuole membrane (PVM), egress, 
or merozoite number per merosome, can be easily and 
quantitatively explored using NanoLuc. Additionally, 
the effect of drugs affecting the host during liver stage 
infections, such as those targeting host cell autophagy, 
can also be accurately evaluated with the highest sen-
sitivity so far reported. Work to evaluate the effects of 
drugs such as rapamycin and chloroquine (an autophagy 
enhancer and inhibitor, respectively) in the context of P. 
berghei egress from the liver is presently ongoing. While 
point-by-point characterization of parasite counts might 
still require parallel assessment with microscopy, Nano-
Luc provides a considerable advantage over microscopy 
for high-throughput screening.
Although the liver stage in general is an attractive tar-
get for blocking parasite development, liver stage egress 
is the key interface between the asymptomatic pre-eryth-
rocytic stage and the clinically symptomatic blood stages. 
Although our group pioneered research on Plasmodium 
egress from host livers a decade ago [101], to this date 
relatively little is known about host and parasite mecha-
nisms affecting egress. The so-called pre-patent period is 
defined as the time between sporozoite inoculation and 
the appearance of Plasmodium parasites in the blood. So 
far, the pre-patent period has been assessed by time-con-
suming or subjective techniques including PCR, fluores-
cence, and light microscopy. In 2014, Zuzarte-Luis et al. 
published a luminescence assay based on firefly luciferase 
whereby first blood stage parasites were detected at 60 h 
post-sporozoite inoculation into mice [15]. Interestingly, 
careful characterization of development and egress in 
previous in vivo work using firefly luciferase detection by 
IVIS, showed that maximal luminescent signal in the liver 
is detected at 44  h post-infection, followed by a grad-
ual decrease in luminescence from 46  h onwards [39]. 
The sharpest decrease in luminescence in  vivo occurs 
between 48 and 56  h post-infection. Previous work by 
Sturm et al. confirmed egress by intravital microscopy, as 
early as 42 h post-infection. Even if the circulating para-
site ‘forms’ in the peripheral bloodstream are merosomes 
en route to sites such as the lungs as has been previously 
proposed [110], it is indeed intriguing that a gap of at 
least 16 h seems to exist between detection of a decrease 
in liver luminescence in  vivo, and detection of erythro-
cytic stages in the bloodstream.
Following inoculation of mice with PbNLuc sporozo-
ites, upon monitoring the peripheral blood for detec-
tion of egressed parasites, luminescence signals were 
detected as early as 36 h post- sporozoite inoculation, 
and consistently strong signals at 40 and 42 h post-infec-
tion supporting previous observations of egress done by 
intravital imaging (Heussler et  al, unpublished). As in 
this study mice were infected in parallel with PbFLuc, 
previously reported observations of an absence of signal 
in peripheral blood at all times prior to 60 h post-sporo-
zoite infection were confirmed [15]. This discrepancy, 
together with the assessment of the enhanced threshold 
of parasite detection of NanoLuc, suggests that lack of 
detection of parasites in the peripheral blood using fire-
fly luciferase at time points prior to 60  h post-sporozo-
ite inoculation is due to insufficient assay sensitivity. To 
confirm the infectious nature of PbNLuc egressed from 
the liver, peripheral blood from sporozoite-infected 
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mice was isolated starting at 36  h post-infection. From 
44  h post-infection onwards, inoculation of this blood 
into naïve mice resulted in the successful establishment 
of blood stage infections thereby confirming the pres-
ence of parasites since these early times (prior to 60  h 
as previously believed). On the other hand, inoculation 
of naïve mice with the blood obtained at 36–42 h post-
sporozoite injection in the donor mice did not result in 
positive infections. It is tempting to speculate that the 
luminescent signal in peripheral blood of the donor 
mice at 36–42 h post-sporozoite injection is arising from 
newly formed merosomes that either contained non-
infectious, immature merozoites or that, upon injection 
of these merosomes into a naïve mouse, the merosomes 
are eliminated for example in the spleen.
Interestingly, upon studying liver stage egress rates 
in 4-hourly periods by monitoring peripheral blood, a 
significant peak in signal increase in peripheral blood 
occurring at 56 h post-sporozoite injection was observed, 
coinciding with the sharpest decrease in liver stage sig-
nal as described previously in  vivo [39]. This suggests 
that initially, egress occurs at very low rates until 56 hpi 
when either large-scale egress of parasites from the liver 
occurs, or merosomes transported to other tissues, such 
as the lungs, rupture at this time point, and release large 
numbers of merozoites into the bloodstream. This sharp 
increase would explain the high signal detected in the 
blood at 60  h post-sporozoite injection, also detectable 
by firefly luciferase. The PbNLuc parasites, and their 150-
fold higher signal than PbFLuc, appear to be an extremely 
valuable tool in the context of evaluating the dynamics of 
egress upon parasite and host alterations, as well as para-
site mutations affecting egress.
A further application explored in this work, was meas-
urement of individual detached cells in vitro. Total quan-
tification of detached cells is a measure of successful 
parasite development throughout the pre-erythrocytic 
stage. Analysis of drugs or mutations affecting param-
eters in parasites or hosts with downstream effects on 
detached cell-formation and egress in  vitro so far relies 
on quantification of total detached cells by fluorescence 
microscopy, which is time-consuming and not very accu-
rate. In addition, in this work NanoLuc was shown to be 
sensitive enough to detect signals from single detached 
cells, and to accurately differentiate between cells with 
different volumes and different loads of merozoites.
Finally, PbNLuc assessment in blood stages was 
equally sensitive as in other stages, allowing visualiza-
tion of luminescent signal from single parasites, and an 
almost perfect correlation of luminescence intensity with 
peripheral blood parasitaemia. PbNLuc was tested in the 
context of sequestration of highly synchronized para-
sites, where bi-hourly measurements of peripheral blood 
showed marked decrease in signal from 18 to 25 h, corre-
sponding with schizont stages in synchronous infections. 
Schizonts are able to sequester in the vasculature and are 
therefore absent from peripheral blood.
As proof of principle of multi-plexing for the PbN-
Luc line, measurements of sequestration of PbNLuc 
co-injected with PbFLuc were performed. The spectral 
profile of NanoLuc has an emission maximum at 460 nm, 
which is 100  nm blue-shifted with respect to Firefly 
luciferase. This is an advantage in terms of multiplex-
ing, as both luciferases can be measured using different 
filters. Furthermore, each of the enzymes requires a dif-
ferent substrate, namely furimazine for NanoLuc, and 
luciferin for firefly luciferase. For Plasmodium research, 
a potential application of NanoLuc in the context of 
multi-plexing, aside of co-infections, is the generation of 
lines whereby each luciferase is expressed under promot-
ers specific to different parasite stages and sub-stages in 
terms of kinetics and localization. So far, staging is reliant 
on subjective, expensive, or extremely time-consuming 
techniques, and therefore this would be a largely benefi-
cial tool of research.
The implementation of blood stage anti-malarial drug 
screening by luminescence has been widespread. Due to 
the higher sensitivity of detection of PbNLuc compared 
to PbFLuc, more sensitive assessment of anti-malarial 
compounds can be performed using this newly intro-
duced line. The kinetics of clearance potential for various 
anti-malarials at various parasite stages is currently being 
explored using PbNLuc.
Finally, a further avenue for the application of this para-
site line explored in this present study, is its use for limit-
ing dilution assays for P. berghei sub-cloning. At present, 
a major hindrance for sub-cloning by limiting dilution of 
blood stages is that large amounts of mice are required 
for injection, theoretically of a single infected iRBC 
which will give rise to a clonal population. Since the use 
of PbNLuc parasites allow visualization of single iRBCs 
without the need for lysis, it was possible to perform lim-
iting dilutions in 96-well plates and assess luminescence 
to detect the presence or absence of parasites prior to 
injection, thereby heavily reducing the mouse demand.
Overall, the advantages of NanoLuc in  vitro surpass 
other luminescence and fluorescence assays for scal-
ability, sensitivity and rapid quantitation. Furthermore, 
NanoLuc exists in a secreted and non-secreted form. 
The secreted form has been used for P. falciparum in the 
context of studying the Plasmodium exportome and traf-
ficking pathways [97]. PbNLuc parasites or other mouse 
Plasmodium strains expressing the secreted form of 
NanoLuc could potentially be used for similar studies of 
protein export, throughout all infection stages, includ-
ing mosquito and liver stages. An additional application 
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of NanoLuc in other fields has been in the context of 
BRET (Bioluminescence Resonance Energy Transfer) 
to study protein–protein and/or receptor-ligand inter-
actions, which would be an extremely valuable tool in 
Plasmodium research. BRET was originally established 
using Renilla luciferase [111–117], however the large size 
and relatively lower brightness of Renilla in comparison 
to NanoLuc, have made the latter a powerful molecule, 
and the current molecule of choice for BRET. Aside from 
receptor-ligand interactions alone, other studies have 
used NanoLuc to study ligand-induced receptor internal-
ization and downstream signalling. Other ‘binding’ pro-
cesses in biology can be equally studied with NanoLuc, 
including antigen–antibody binding, lectin-carbohydrate 
binding, protein–protein interactions, and protein-
nucleic acid interactions, among others. In the context of 
Plasmodium research at the host and parasite interfaces, 
the use of BRET could be a powerful tool to replace other 
time-consuming or expensive assays currently in use.
Although the spectral profile difference of NanoLuc 
compared to the other luciferases is an advantage in vitro, 
the use of blue-shifted luciferases in vivo poses an impor-
tant challenge, as short wavelengths do not readily pen-
etrate mammalian tissues [70]. Although other work has 
used NanoLuc for characterizing events at skin level, 
imaging of deep organs in living mice, including the 
liver, lungs, spleen, and brain was attempted in this study 
and was found to be unsuccessful. The use of an equally 
bright assay in  vivo would be highly advantageous for 
Plasmodium research to study low-density infections, 
and parasite migration within different organs of the 
mice. Previous work using targeted mutagenesis has led 
to the generation of red-shifted Renilla [118], Click beetle 
[47], and firefly [119] luciferases to increase their sensi-
tivity upon in vivo use for imaging deep tissues. As red-
shifting of these luciferases has proven to be successful, a 
similar approach might be envisaged for NanoLuc.
Conclusion
Overall, PbNLuc is presented here as a parasite line with 
on average, 150-fold higher luminescence intensity than 
firefly luciferase. This novel tool enabled extremely sen-
sitive and efficient evaluation of parasites at low densi-
ties, and detection of even small variations in parasite 
development at all stages. As such, this line represents 
a valuable tool for characterization of genetic mutations 
affecting various developmental stages throughout the 
entire P. berghei life cycle, as well as interventions such as 
testing of drug or vaccine targets, affecting parasite-host 
interactions, or drugs affecting host responses that hin-
der or enhance parasite development and growth.
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